1st Base

Executive Summary

1st Base is a Singapore-based contract research and manufacturing organization (CRO/CDMO) specializing in molecular biology, genomics, and custom research services. Founded in 2020, the company has rapidly built a platform that integrates high-throughput sequencing, bioinformatics pipelines, and in-house reagent production, enabling fast turnaround and quality-controlled deliverables for academic, biotech, and pharmaceutical clients. By covering the full drug discovery lifecycle, from early research to custom manufacturing, 1st Base addresses the growing demand for specialized, outsourced genomics and molecular biology services in the Asia-Pacific region. The company's location in Singapore, a global biotech hub, further positions it to capture cross-border partnerships and regional expansion opportunities. With an employee base of 50-200 and a focus on innovation, 1st Base is well-placed to benefit from the increasing reliance on outsourced R&D and the expansion of precision medicine. Its in-house reagent production reduces supply chain risks and improves margins, while its platform model allows scalability. The company's recent traction suggests strong demand for its services, and it may be seeking growth capital to expand capacity and develop new offerings. Given its strategic location and comprehensive service suite, 1st Base has the potential to become a key partner for biopharma firms in Asia.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round70% success
• Q4 2026Major Partnership with a Top-20 Pharma Company50% success
• Q3 2026Expansion of Sequencing Capacity or New Service Launch60% success